DUAL Antithrombotic Therapy in Patients With AF and ACS
A phase 4 trial registered on ClinicalTrials.gov. The registry status is unknown. It plans to enroll 4000 participants.
Also called NCT04023630
- Study
- In this atlas
Overview
- Design
- Interventional study; randomized; no masking; primary purpose treatment
- Phase
- Phase 4
- Enrolled
- 4,000 participants
- Registry
-
NCT04023630
-
- Planned start
- (anticipated)
- Primary completion
- (anticipated)
- Completion
- (anticipated)
- Countries
- Not reported
- Registry status
- Unknown status
Technical summary
Registry record NCT04023630. Randomized; no masking; primary purpose treatment. Start 2019-10-01 (anticipated); primary completion 2020-09-30 (anticipated). Results not posted.
The registry's words
Labels as the registry gives them, not rewritten.
- Brief title
- DUAL Antithrombotic Therapy in Patients With AF and ACS
- Condition
- Atrial Fibrillation
- Condition
- Acute Coronary Syndromes
- Intervention (Drug)
- Rivaroxaban 15 MG Oral Tablet
- Intervention (Drug)
- Clopidogrel 75 Mg Oral Tablet
- Intervention (Drug)
- Ticagrelor 90 MG Oral Tablet
- Lead sponsor
- Second Affiliated Hospital, Zhejiang University, School of Medicine
Record details
- Record id
cardio:ct-nct04023630- Content hash
3bc3e1681b07142af267a6723a37909cf88a6dd7a7d3e5df57ea1982e057bc3b